|Systematic (IUPAC) name|
|Mol. mass||201.176 g/mol|
HYDIA is a drug that is used in neuroscience research, which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors (mGluR2/3). It has been useful in the mapping of the group II mGluR receptor proteins and their molecular modeling. HYDIA is similar in structure to group II mGluR agonists such as eglumegad and LY-404,039, but the addition of the 3-hydroxy group reverses the activity to a competitive antagonist. Other derivatives such as the 3-benzyloxy ether are more potent antagonists than HYDIA itself.
- Lundström L, Kuhn B, Beck J, Borroni E, Wettstein JG, Woltering TJ, Gatti S (July 2009). "Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA". Chemmedchem 4 (7): 1086–94.
- Woltering TJ, Adam G, Huguenin P, Wichmann J, Kolczewski S, Gatti S, Bourson A, Kew JN, Richards G, Kemp JA, Mutel V, Knoflach F (February 2008). "Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA". Chemmedchem 3 (2): 323–35.